Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,461 total articles
Ally beat on key operational objectives in Q3: higher-yielding loan growth, improving capital returns, and intact credit metrics. The stock trades below recent highs on a pullback; fundamentals and valuation leave room for a re-rate. This is a mid-term trade idea with clear entry, stop, and target.
Equifax (EFX) beat Q3 estimates with $1.69B revenue and $2.26 EPS, while management trimmed 2026 revenue guidance on weak mortgage activity. Recent wins - including a $550M annual government contract and faster VantageScore adoption - plus AI efficiency gains argue for re-rating from today’s ~$20.7B market cap. This is a tactical long thesis: entry…
FEIM's recent pullback has left the stock below key moving averages and trading with an oversold RSI, but fundamentals - a $71M backlog, clean balance sheet and fresh capital from a July offering - argue for a mid-term rebound. This trade idea lays out entry, stop and target levels with a 45-trading-day horizon.
Array Technologies (ARRY) carries a large orderbook, but a mismatch between booked revenue and cash conversion, weakening top-line trends and heavy short interest make the shares a high-risk short. Trade plan: short at $3.35, stop $4.00, target $2.20 over a mid term (45 trading days) horizon.
<p>Gladstone Investment (GAIN) trades at a sub-1.0 price-to-book, yields roughly 6.4% and is showing signs of NAV recovery as floating-rate assets benefit from higher rates. That combination makes it attractive for an income-oriented tactical long, but the position comes with outsized credit and liquidity risk for a small-cap BDC. This trade lays o…
Harmony Biosciences (HRMY) runs a predictable commercial engine with WAKIX generating steady growth and outsized free cash flow. The shares trade at a modest multiple for a single-product commercial-stage drugmaker, giving a favorable risk-reward on dips. That said, an imminent patent ruling is a binary event that can rapidly reprice the stock. The…
KeyCorp's Q3 print surprised to the upside and management's funding-cost stabilization is translating into meaningful net interest income growth. At $20.81, Key trades at ~11.8x earnings with a 4.7% yield and cheap book value support. We upgrade to Buy and propose a tactical swing trade to capture NII momentum and potential re-rating into year-end.
Cinemark (CNK) looks positioned to capture upside from a stronger film slate into 2027 and continued pricing power from premium formats. The stock trades at a reasonable multiple relative to cash flow (EV/EBITDA 9.3) and produces meaningful free cash flow ($325M). This trade idea lays out a disciplined long entry, stop and target for a 180-trading-…
ServiceNow is shifting its monetization from traditional seat-based licensing toward higher-value 'assists' and AI-driven execution layers. With Q2 2026 revenue at $4.0B (up 24% y/y), more than $1B in AI-related ACV, $4.58B in free cash flow and a market cap near $155B, the set-up favors a measured long trade. We lay out an entry at $149.57, a stop…
Monolithic Power Systems earned a meaningful upgrade after recent analyst revisions and improving earnings momentum. The company's exposure to AI infrastructure, data-center power delivery and steady FCF supports a re-rating despite a premium multiple. This trade idea lays out an entry, stop and target for a long-term campaign and the key catalysts…
Auna S.A. (AUNA) looks attractive here: improving hospital volumes and clinic throughput are showing up in price momentum, the stock trades at a low price-to-book (PB 0.73) with a market cap of roughly $401M, and technicals are constructive. We lay out a mid-term (45 trading days) trade plan: enter at $5.43, stop $4.70, target $7.00.
Onto Innovation pulled back into the $210s after a torrid run. Fundamentals - including record Q2 revenue, a $1.1B backlog and large strategic investments - support another leg of growth into 2027. This trade idea argues for a measured long with an entry at $220.00, a $360.00 target and a $190.00 stop, timed for the long-term ramp into 2027 (180 tr…
Montauk Renewables (MNTK) is posting an earnings recovery that has lifted estimates and investor interest. At a market cap near $296M and an EV/EBITDA of ~6.2, the stock offers upside toward prior highs if operational trends hold. However, negative free cash flow and a sub-1.0 current ratio leave the balance sheet as the primary constraint; this id…
Inogen is a focused player in portable oxygen concentrators. The stock trades at bargain valuation metrics (EV ≈ $86.6M, P/S ≈ 0.49, P/B ≈ 1.0) and recently found a base around $5.05. This idea is a structured long: entry $6.69, stop $5.05, target $9.50, with a primary horizon of long term (180 trading days). Risks include margin pressure, competit…
Silicom is a compact, specialized player in networking and data infrastructure that recovered sharply from last winter's low. With a market cap of roughly $233M, a thin float, rising volume and an upcoming Q3 earnings event, the risk/reward looks favorable for a mid-term tactical long. Technicals are mixed but momentum indicators suggest the stock …
BlackBerry is showing tangible signs of a business inflection: QNX revenue and backlog are growing, adjusted EBITDA and free cash flow have improved, and management is raising guidance. The stock trades well below its 52-week highs but carries a premium multiple versus its historical medians. For traders, a disciplined long with a clear stop and tw…
CoreWeave has been punished this month on rising rates and refinancing fears. The sell-off looks overdone relative to demand fundamentals: 112% YoY revenue growth, a $104 billion backlog, a major customer/partner in Nvidia, and an enterprise value that already prices in meaningful execution risk. This trade lays out a defined-entry long with a clea…
Intercontinental Exchange (ICE) looks like a buy around $158.6. The market is focused on the Mortgage Technology segment's cyclical pain, but ICE's Exchanges, Data and Clearing businesses are generating recurring, high-margin cash flow that supports buybacks, M&A and multiple expansion if volumes stabilize. Trade plan: enter at $158.61, stop $146.0…
Autodesk is a dominant design-software franchise trading at roughly $245 and a market cap near $51.3B. The business produces strong free cash flow ($2.84B trailing) and high returns on equity, yet the stock sits well below its 52-week high. This trade idea targets capital appreciation over a multi-month horizon with a disciplined stop to protect ag…
Madrigal (MDGL) has a blockbuster-approved MASH drug and an active pipeline, but the stock looks like it’s being graded for an ideal commercial ramp rather than a self-funding franchise. With a market cap near $10.8B, negative free cash flow, and valuations implying rapid revenue growth, this trade idea targets a mid-term pullback back toward the p…
Standard Chartered has been re-rated off a depressed base as capital and returns have trended better and Asia trade finance and FX flows re-accelerate. We like a controlled long with a $12.50 entry, $16.00 target and $10.00 stop — horizon 180 trading days — because upside comes from both multiple expansion and steady earnings recovery.
WillScot is an asset-heavy modular space rental business trading at $16.25 after a protracted reset. The balance sheet looks leveraged but cash flow is healthy: free cash flow ran roughly $522M and EV/EBITDA is a modest 7.2x. This trade views recent weakness as a re-pricing tied to customer mix shifts rather than fleet deterioration. A mid-term swi…
Sanofi (SNY) is trading near its 52-week low while core growth drivers - led by Dupixent - are still accelerating and the stock yields ~4.5%. Given a $100.4B market cap, a modest P/E and steady cash returns, the market looks to be overpricing pipeline risk. We like a defined long trade at $41.00 with a $46.00 target and a $38.50 stop over a mid-ter…
UnitedHealth (UNH) reported a crisp operational beat in Q3 driven by improving Optum margins and AI-enabled workflow gains. With Q3 revenue of $113 billion, raised 2026 EPS guidance to at least $20.50 and Optum margins expanding to 5.6%, the risk/reward supports a long trade. My plan: enter at market near $419.29, stop $385.00, target $480.00 on a …
McEwen (MUX) is trading near its 52-week low but has been actively de-risking its balance sheet and advancing high-return projects. With roughly $980M market cap, a sizeable short position and several near-term corporate/cash catalysts, there is a tactical opportunity to buy a controlled position. This idea is a mid-term swing trade that banks on c…
